Clinical Trials Browser

Stomach Neoplasms

NCT05887609 2026-06-04

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Phase 2 Recruiting

53 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06607692 2026-06-04

LUPARPED

Phase 1/2 Recruiting

25 enrolled

CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

Clinical Trials

Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

LUPARPED

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

POINT

TAPUR

A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

ENDOLA

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

ORCA-2

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

RAINBO

Study of Pamiparib in Newly Diagnosed and rGBM

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

I-SPY

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Selumetinib and Olaparib in Solid Tumors

CAPRI

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

PIPSeN

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

ORCHID

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

PLANET

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

RADIOLA

DAPA-ARMOR

PROOV

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Surgical Pembro +/- Olaparib w TMZ for rGBM

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

DOVACC

RADIOSARP

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

ATARI

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer